ISLAMABAD: A groundbreaking business-to-business (B2B) agreement between Pakistan and China has been signed to expedite the availability of modern treatment for Hepatitis Delta Virus (HDV) in Pakistan, marking a significant milestone in public health collaboration between the two nations.
The agreement was formalized during a high-level meeting in Islamabad, attended by Federal Minister for Health Mustafa Kamal, Dr. Bin Chen (CEO of Huahui Health), Professor Dr. Saeed S. Hamid (prominent hematologist), Syed Munawar Ali (clinical research expert), Federal Secretary Health Aslam Ghauri, and Dr. Obaid (CEO of DRAP).
Federal Minister for Health Mustafa Kamal hailed the agreement as a major success, emphasizing its role in ensuring early access to advanced HDV treatments for Pakistani patients. He stated:
With over 1 million people in Pakistan estimated to be infected with HDV, the agreement aims to enhance access to cutting-edge therapies, strengthen local pharmaceutical capacity, and foster international cooperation in healthcare.
The Drug Regulatory Authority of Pakistan (DRAP), meanwhile, is prioritizing all legal and regulatory requirements to ensure the swift availability of the medication to patients.
Additionally, Phase Two clinical trials of the HDV treatment have already demonstrated positive results in safety and efficacy, further validating its potential impact.





